FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fins de pesquisa apenas. Leia o disclaimer completo →

Biblioteca de Peptídeos

Gonadorelin

GnRH / LHRH / Factrel / Lutrepulse

Sexual Health

Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH), identical in structure to the endogenous hypothalamic decapeptide that controls reproductive hormone secretion. When administered in pulsatile fashion, it stimulates the anterior pituitary to release both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is used clinically for diagnostic testing of pituitary function and therapeutically to maintain fertility during testosterone replacement therapy.

Mecanismo de Ação

Synthetic analog of endogenous gonadotropin-releasing hormone (GnRH). Pulsatile administration stimulates FSH and LH release from the anterior pituitary. Continuous administration paradoxically downregulates the HPG axis through receptor desensitization.

Protocolos de Pesquisa

Para fins de pesquisa apenas. Não é conselhos médicos.

Pulsatile protocols use 25-100mcg subcutaneously every 90-120 minutes via pump to mimic natural GnRH pulses. Diagnostic test protocols use a single 100mcg IV dose. Continuous dosing protocols (suppressive) not commonly used with the native peptide.

Notas de Pesquisa

Clinical Research Status

Gonadorelin has FDA approval as a diagnostic agent (Factrel) for evaluating pituitary gonadotroph function and in pulsatile form (Lutrepulse) for hypothalamic amenorrhea, though the latter formulation has been discontinued. It is increasingly prescribed off-label by TRT clinics as an alternative to HCG for maintaining LH/FSH secretion and testicular function. Current research focuses on its role in preserving spermatogenesis during exogenous testosterone administration.

Key Published Findings

Pulsatile GnRH administration has been demonstrated to restore ovulation in women with hypothalamic amenorrhea with pregnancy rates of 20-30% per cycle. In male patients on TRT, subcutaneous gonadorelin at doses of 100-400 mcg administered two to three times daily can maintain measurable LH and FSH levels. The pulsatile pattern is critical as continuous administration paradoxically suppresses gonadotropin release through receptor downregulation.

Safety Profile

Gonadorelin has an excellent safety profile with minimal systemic side effects when used at appropriate doses. Injection site reactions are the most commonly reported adverse event. Headache, flushing, and abdominal discomfort occur rarely. The main clinical concern is ensuring pulsatile rather than continuous dosing patterns to avoid the paradoxical suppressive effect seen with GnRH agonists.

Comparison to Related Compounds

Unlike HCG which directly stimulates Leydig cells, gonadorelin works upstream by stimulating the pituitary to release endogenous LH and FSH, maintaining more physiological hormonal signaling. Compared to GnRH agonists like leuprolide or triptorelin, gonadorelin at pulsatile doses stimulates rather than suppresses the reproductive axis. It offers a more physiological approach to fertility preservation during TRT but requires more frequent dosing than HCG.

Community Observations

Gonadorelin gained significant popularity after 2020 when compounded HCG became harder to obtain, with many TRT clinics switching patients to gonadorelin protocols. Practitioners note that effective use requires proper dosing frequency (typically twice daily subcutaneous injections) to mimic natural GnRH pulsatility. Some clinicians report that gonadorelin is less reliably effective than HCG for testicular size maintenance, though individual responses vary.

Meio-Vivo

~2-4 minutes

Reconstituição

Bacteriostatic water (BAC)

Armazenamento

Liofilizado

Refrigerate 2-8C up to 12 months.

Reconstituído

Refrigerate 2-8C. Use within 14 days.

Situação Legal nos EUA

FDA-approved for diagnostic use (Rx only)

Também Conhecido Como

GnRHLHRHFactrelLutrepulse

Perguntas frequentes

O que é Gonadorelin?

Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH), identical in structure to the endogenous hypothalamic decapeptide that controls reproductive hormone secretion. When administered in pulsatile fashion, it stimulates the anterior pituitary to release both luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It is used clinically for diagnostic testing of pituitary function and therapeutically to maintain fertility during testosterone replacement therapy.

Como Gonadorelin funciona?

Synthetic analog of endogenous gonadotropin-releasing hormone (GnRH). Pulsatile administration stimulates FSH and LH release from the anterior pituitary. Continuous administration paradoxically downregulates the HPG axis through receptor desensitization.

Qual é o status regulatório de Gonadorelin nos EUA?

FDA-approved for diagnostic use (Rx only)

Qual é a meia-vida de Gonadorelin?

~2-4 minutes

Por quais outros nomes Gonadorelin é conhecido?

GnRH, LHRH, Factrel, Lutrepulse

Peptide Contacts fornece resumos baseados em pesquisas apenas para fins informativos. Não hospedamos, distribuímos ou endossamos documentação de fornecedores. Todas as certificações de análise completa, certificados GMP e comunicações de fornecedores devem ser solicitadas e verificadas diretamente pelo comprador. Nada nesta plataforma constitui conselhos legais, médicos ou profissionais. Os usuários são unicamente responsáveis por verificar as credenciais dos fornecedores e garantir a conformidade com todas as leis locais, estaduais e federais aplicáveis antes de adquirir qualquer química de pesquisa. O uso desta plataforma constitui aceitação plena da responsabilidade pessoal.

Leia a declaração completa